International Association of
Therapeutic Drug Monitoring and Clinical Toxicology
Fostering education, research and practice in TDM and CT

15th Annual Congress - Kyoto 2017- Post Congress Symposium

September 28, 2017 │ Kyoto, Japan
Kyoto 2017 Congress, Expansion and Evolution of TDM and CT
Post Congress Symposium Sessions

yyyy-mm-dd Type Link Title and Presenters

2017-9-28 Post Congress Symposium “Guidelines and Consensus Documents for TDM” YouTube icon full color

IATDMCT Consensus Document on TDM of Everolimus
Maria Shipkova

[+] View Bio

Keywords: everolimus, guideline, immunosuppressive, analytics

 

shipkovaMaria Shipkova
MD, FEBLM, DR. (BG)
Medical Head of the central TDM section
SYNLAB MVZ Leinfelden-Echterdingen GmbH
Stuttgart, Germany

 

Maria Shipkova completed her medical education at the Medical University, Sofia, Bulgaria, and graduate with a doctorate in medicne. She specialized in Laboratory Medicine and joined in 1992 the TDM laboratory headed by Prof. Dobrin Svinarov, Chair for Clinical Laboratory, Sofia. In 1995 Dr. Shipkova was awarded a Tempus Phare postdoctoral fellowship from the European Union to extend her education in Therapeutic Drug Monitoring at the Department of Clinical Chemistry, Georg-August-University, Goettingen under the supervision of Prof. Michael Oellerich. At the conclusion of this appointment she finished her MD thesis at the Georg-August-University and remained in Goettingen as a resident and was involved in a variety of routine and research activities in the field of transplantation medicine and immunosuppressive drug monitoring. In 2003 Dr. Shipkova moved to Stuttgart, where she now pursues her work in Therapeutic Drug Monitoring as the Medical Head of the central TDM section at SYNLAB MVZ Leinfelden-Echterdingen GmbH , Klinikum Stuttgart.

 

Her research interests are focused on drug metabolism & drug toxicity, development & evaluation of analytical methods, Therapeutic Drug Monitoring of immunosuppressive drugs, and most recently biomarkers as a tool to optimize immunosuppression.

 

Dr. Shipkova has authored over 110 peer-reviewed publications. She is the past Chair of the Immunosuppressive Drugs Scientific Committee at IATDMCT (2013-2015) and was, together with Professor David W. Holt (London, UK), the coordinator of the “Consensus Document on TDM of Everolimus”.

 

In 2005 Maria Shipkova was awarded the IATDMCT Young Investigator Award. She is currently IATDMCT Secretary, Vice-Chair of the IATDMCT Communication Committee and Review’s Editor for the IATDMCT Journal “Therapeutic Drug Monitoring”.


2017-9-28 Post Congress Symposium “Guidelines and Consensus Documents for TDM” YouTube icon full color

Guidelines on Therapeutic Drug Monitoring of Immunosuppressive Drugs Used in Organ Transplantation in Japan
Satohiro Masuda

[+] View Bio

Keywords:

 

Satohiro Masuda
Professor & DIrector
Department of Pharmacy, Kyushu University Hospital
Fukuoka, Japan

 


2017-9-28 Post Congress Symposium “Guidelines and Consensus Documents for TDM” YouTube icon full color

Analytical methods of Measurement for Immunosuppressive Drug Concentrations
Pawel Kunicki

[+] View Bio

Keywords:

 

Pawel Kunicki
Clinical Pharmacology Unit, Institute of Cardiology
Warszawa, Poland

 


2017-9-28 Post Congress Symposium “Guidelines and Consensus Documents for TDM” YouTube icon full color

Dried blood spot analysis: Are we ready for implementation?
Christophe Stove

[+] View Bio

Keywords:

 

stove 150x200Christophe Stove
Professor, University of Ghent
Ghent, Belgium

 


2017-9-28 Post Congress Symposium “Guidelines and Consensus Documents for TDM” YouTube icon full color

Guidelines for Therapeutic Drug Monitoring of Cardiovascular Drugs
Tsuyoshi Shiga

[+] View Bio

Keywords:

 

Tsuyoshi Shiga
Tokyo Women's Medical University
Tokyo, Japan

 


2017-9-28 Post Congress Symposium “Guidelines and Consensus Documents for TDM” YouTube icon full color

Therapeutic Drug Monitoring of 5-Fluorouracil: An Approach Whose Time Has Come
Edward Chu

[+] View Bio

Keywords: TDM, personalized medicine, cancer chemotherapy, 5-fluorouracil, colorectal cancer

 

Edward Chu
Professor of Medicine and Pharmacology & Chemical Biology
Chief of the Division of Hematology-Oncology
Deputy Director of the UPMC Hillman Cancer Center (HCC)
Pittsburgh, USA

 

Dr. Edward Chu is Professor of Medicine and Pharmacology & Chemical Biology, Chief of the Division of Hematology-Oncology, and Deputy Director of the UPMC Hillman Cancer Center (HCC). He serves as Co-Leader of the HCC Cancer Therapeutics Program, which is one of the main research programs of the cancer center, and he is Director and PI of the Phase I Program, which is one of only 11 centers in the US to be funded by the National Cancer Institute.

 

Dr. Chu specializes in the treatment of colorectal and GI cancers. His clinical and translational research efforts have focused on identifying novel drugs and combination regimens for colorectal cancer and other GI cancers. In particular, he has focused on developing early-phase I/II clinical trials. He also has a very strong interest in integrating Chinese herbal medicine with standard cancer chemotherapy with the goal of enhancing clinical activity and reducing the toxicity associated with chemotherapy.

 

His basic research interests have focused on characterization of the molecular mechanisms underlying the development of cellular drug resistance in the treatment of colorectal cancer, especially as it relates to the fluoropyrimidine class of anticancer agents. His research group was the first to identify translational autoregulation as a novel regulatory mechanism in eukaryotes for controlling the expression of the folate-dependent enzymes, thymidylate synthase and dihydrofolate reductase. More recently, his research lab has focused on identifying and developing Chinese herbal medicines as new treatments for colorectal cancer and other GI cancers.

 

Dr. Chu is a member of several professional and scientific associations including American Society of Clinical Oncology, European Society of Medical Oncology, American Association for Cancer Research, American Association for the Advancement of Science, and American College of Physicians. He also serves on the scientific advisory boards of several NCI-designated cancer centers, including Albert Einstein, Dartmouth, Case Western Seidman Cancer Center, Columbia, Duke Cancer Institute, University of Southern California, Medical University of South Carolina, University of Michigan, Karmanos Cancer Center, University of Kentucky, and University of Arizona.


2017-9-28 Post Congress Symposium “Guidelines and Consensus Documents for TDM” YouTube icon full color

Personalizing Busulfan Exposure in Hematopoietic Cell Transplantation: Current consensus and discrepancy
Erik van Maarseveen

[+] View Bio

Keywords: Busulfan; Therapeutic drug monitoring; Hematopoietic Cell Transplantation (HCT)

 

van maarseveen 150x200Erik van Maarseveen
Clinical Pharmacist
University Medical Center Utrecht
Utrecht, The Netherlands

 

Dr. Erik van Maarseveen got his Pharmacy Degree in 2005 and started his career as a pharmacist at the Gouda Hospital (The Netherlands). That same year he obtained the Certificate of Fundamentals of Business & Economics for Beta’s as part of the Master program “Business and Economics for Beta’s” at Utrecht University. His 4-year-training as a hospital pharmacist commenced in 2006 at Central Hospital Pharmacy, The Hague and the Gouda Hospital. Dr. van Maarseveen has been working as a registered hospital pharmacist since 2010 at the University Medical Center Utrecht (The Netherlands), where he leads the therapeutic drug monitoring and toxicology laboratory which is equipped with GC, HPLC, UPLC, LC-MSMS and Orbitrap-LCMS technologies. Dr. van Maarseveen and his team develop bio-analytical assays primarily for therapeutic drug monitoring and clinical toxicology purposes with the ultimate goal to improve treatment outcomes. Directly after he obtained his PhD on optimizing treatment of once daily dosed aminoglycosides and continuously infused vancomycin in 2014, he embarked on his clinical pharmacologist training, which he completed in 2016. Currently, his research focusses on clinical pharmacology and bioanalysis in solid organ and stem cell transplantation, infectious diseases, cystic fibrosis and oncology. Among others, he is co-applicant of a grant of the Dutch KiKa (Children Cancerfree) foundation awarded to investigate the pharmacology of conditioning agents in stem cell transplantation conditioning. Van Maarseveen is a member of the TDM in Oncology scientific committee of the IATDMCT association, chair of the special interest group on Transplantation and member of the committee on Analysis & Toxicology of the Dutch Association for Hospital Pharmacists. In 2016, he was installed as a board member of the Dutch Association for Quality Assessment in Therapeutic Drug Monitoring and Clinical Toxicology. Van Maarseveen is a member of pharmacy steering committee of the European Society for Bone Marrow Transplant. Furthermore, Dr van Maarseveen, who is in possession of a university teaching qualification, teaches pharmacology, TDM and toxicology to both pharmacy and medical students at Utrecht University and in 2017 he was elected as a Direction of Education within the IATDMCT association. Dr van Maarseveen has published over 40 peer-reviewed papers (https://www.researchgate.net/profile/Erik_Van_Maarseveen2), acts as a reviewer for multiple clinical and pharmacology journals and has served as an invited speaker and sessions chair on multiple (inter)national congresses. In 2015 he was granted the award for best publication by the Dutch Association for Hospital Pharmacists.


2017-9-28 Post Congress Symposium “Guidelines and Consensus Documents for TDM” YouTube icon full color

Guidelines for Therapeutic Drug Monitoring of Imatinib
William Clarke

[+] View Bio

Keywords:

 

Clarke 150x200William Clarke
Associate Professor, Pathology
Johns Hopkins School of Medicine
Baltimore, USA

 

2017-9-28 Post Congress Symposium “Guidelines and Consensus Documents for TDM” YouTube icon full color

Guidelines for Therapeutic Drug Monitoring of Antiepileptic Drugs
Toshiaki Sendo

[+] View Bio

Keywords: